The present report describes the improved ocular retention and aqueous humoral drug availability of ganciclovir (GCV) when administered via topical instillation of different kind of nanoparticles onto the rabbit eye. GCV was loaded into PLGA nanoparticles, chitosancoated nanoparticles and chitosan-coated niosomal nanoparticles. All three formulations contained nanoparticles equally round in shape with a mean particle size in the range of 180-200 nm. The ocular corneal retention property was evaluated by gamma scintigraphy, revealing that the clearance was slowest in the case of the chitosancontaining formulations. GCV in chitosan-coated PLGA nanoparticles and chitosan-coated niosomal nanoparticles showed approx. 6-fold higher aqueous humor drug availability as compared to a GCV solution and nearly 2.5-fold higher as compared to the chitosan-lacking GCV-PLGA nanoparticles. The results indicate that the use of a mucoadhesive chitosan coating can improve the ocular residence time and aqueous humoral availability of GCV when administered topically in nanoparticles.
Introduction
Ganciclovir (GCV) is a synthetic acyclic nucleoside analog of 2′-deoxyguanosine, exhibiting antiviral activity against herpes simplex virus and cytomegalovirus at relatively low inhibitory concentrations [(IC50 of ∼50 to 500 ng/mL, respectively] (1, 2). GCV plays an important role in the treatment of ocular viral infections. Conventional treatment involves the oral administration of GCV at a dose of 3 g/day. However, this relatively high dose regimen is associated with the occurrence of side effects including bone marrow suppression and neutropenia (1, 3) . Compared to systemic treatment, intravitreal injection of GCV provides higher intraocular drug concentrations but repeated intravitreal injections are poorly tolerated (4) . Topical ocular delivery of GCV is also an option, but its hydrophilic character and rapid elimination will result in poor intraocular availability of the drug. The tear film as well as the corneal and conjunctival epithelia represents a compact barrier hindering the absorption of topically applied hydrophilic drugs into the intraocular region. Therefore, topical delivery of GCV is associated with a low aqueous humor bioavailability (5) (6) (7) (8) . This limitation encourages the development of mucoadhesive GCV nanoformulations for topical ocular delivery with the aim to attain a higher aqueous humoral availability allowing the administration of lower topical doses and reduction of dosing frequency. Thus, the objective of this work was to evaluate the topical ocular retention and increased intraocular delivery of GCV when administered topically entrapped in mucoadhesive nanoparticles as compared to topical ocular delivery of a GCV solution and nanoparticles without mucoadhesive coating. In this study, PLGA nanoparticles and niosomes have been prepared and evaluated. PLGA, being a biodegradable, biocompatible and FDA-approved polymer as drug carrier and medical device is an obvious choice for topical ophthalmic formulation. Moreover, niosomes have already been investigated as a potential topical ocular drug delivery system for many drugs categories such as antiglaucoma and antibiotics (9, 10) .
These vesicles appear to be similar to liposomes in terms of their physical properties. They are also prepared in the same way and, under a variety of conditions, and form unilamellar or multilamellar structures. Niosomes have been claimed to alleviate some of the disadvantages associated with liposomes, such as relatively high cost (11) . They also have the potential for controlled and targeted drug delivery (9, 10).
Materials and methods

Chemicals
A gift sample of GCV was provided by Ranbaxy Laboratories Ltd. (Gurgaon, Haryana, India). Poly (lactide-co-glycolide) (PLGA, Resomer ® 503H, lactic acid/glycolic acid, 50:50) was purchased from Boehringer Ingelheim (Germany). Chitosan (CS, high density, deacetylation degree > 80%) was received as a gift sample from India Sea Foods, Cochin (India). Span 60 and cholesterol were purchased from S.D. Fine-chem Ltd. (Mumbai, India). Acetonitrile and trifluoroacetic acid (TFA) of HPLC grade were obtained from Qualigens Fine Chemicals (Mumbai, India). Water was produced in the laboratory by a Milli-Q purification system (Millipore, Billerica, MA, USA). All other reagents used were of analytical grade.
Preparation of GCV nanocarriers Preparation of PLGA nanoparticles (GCV-NPs)
GCV-NPs were prepared by a double emulsion solvent evaporation method (12) . Briefly, 100 μL of phosphate buffered saline (PBS; pH 7.4) containing GCV (0.4% w/v) was emulsified in 1 mL dichloromethane containing 100 mg PLGA by sonication. The resulting primary emulsion was added to 20 mL of polyvinyl alcohol (PVA, 1.5% w/v in distilled water) with continuous stirring to form a double emulsion. The emulsion was stirred at 1500 rpm until complete evaporation of dichloromethane was achieved. The resulting nanosuspension was subjected to 3 cycles of homogenization at a pressure of 10,000 bar (EmulsiFlex-C5, Avestin, Inc., Canada). GCV-NPs were collected by centrifugation at 15,000 rpm for 10 min at 4°C, washed three times with distilled water, and Lyophilization was carried out in a freezedrier (Heto DRYWINNER, Germany) at 0.05 mBar for 24 h. The entrapment efficiency for the GCV in prepared formulation was then determined using the method reported by Duvvuri et al. (13) by UPLC quantification technique.
Preparation of chitosan-coated PLGA nanoparticles (GCV-CSNPs)
GCV-CSNPs were prepared using a water-oil-water (w/o/w) emulsion solvent evaporation method with slight modification (12) . 100 μL of PBS (pH 7.4) containing GCV (0.4% w/v) was emulsified in 1 mL dichloromethane containing 100 mg PLGA by sonication. The resulting primary emulsion was added to 20 mL of a mixed solution consisting of chitosan (CS) (0.25% w/v in 0.5 M acetate buffer, pH 4.4) and polyvinyl alcohol (PVA, 1.5% w/v in distilled water) with continuous stirring to form a double emulsion. The emulsion was stirred at 1500 rpm until complete evaporation of dichloromethane was achieved. The resulting nanosuspension was subjected to 3 cycles of homogenization at a pressure of 10,000 bar (EmulsiFlex-C5, Avestin, Inc., Canada). GCV-CSNPs were collected by centrifugation at 15,000 rpm for 10 min at 4°C, washed three times with distilled water, and freeze-dried for 24 h. The entrapment efficiency for the GCV in prepared formulation was then determined using the method reported by Duvvuri et al. (13) by UPLC quantification technique.
Preparation of chitosan-coated niosomal nanoparticles (GCV-NDs)
GCV-NDs were prepared by the reverse-phase evaporation technique (1) . Briefly, GCV-loaded niosomes were prepared by dissolving Span 60 and cholesterol in the ratio of 3:2 w/w in diethyl ether and adding 2 mL of PBS (pH 7.4) containing GCV. The mixture was sonicated for 5 min and a thick emulsion was obtained which was stirred at 1500 rpm to remove any residual ether. To this emulsion 3 mL of PBS was added in order to hydrate the vesicles. The resulting vesicles were incubated for 2 h with a 0.2% w/w chitosan solution (in glacial acetic acid, 0.5% v/v, pH 5.5). GCV entrapment (%) was then estimated as per the method reported by Akhter et al. (1) .
GCV quantification
GCV analysis was performed using a Waters Acquity ultra performance liquid chromatography (UPLC) system (Milford, MA, USA) equipped with a binary solvent manager, an autosampler, column manager composed of a column oven, a precolumn heater and a photo diode array detector. 5 μL of the final analytical solution was injected into a Waters Acquity second generation bridged ethyl hybrid (BEH) C18 (50 mm × 2.1 mm, 1.7 μm) UPLC column kept at 50°C. The mobile phase consisted of a mixture of 0.1% TFA in water (adjusted to pH 3.5 using 5.0% dilute ammonia) and acetonitrile (95:5, v/v). The flow rate was 0.45 mL/min and detection was performed at a wavelength of 254 nm with total run time of 3 min. Data acquisition, data handling and instrument control were performed by Empower Software v1.0.
Characterization of GCV nanocarriers
Transmission electron microscopy
The surface morphology of the GCV nanoformulations was studied by transmission electron microscopy (TEM). Formulations treated on copper grids (Polysciences, Warrington, PA) with 1% uranyl acetate for negative staining, followed by sample drying, were analyzed by TEM (Philips CM 10, The Netherlands) at an accelerating voltage of 100 kV.
Particle size distribution and zeta potential
The mean particle size of the GCV nanoformulations was determined by photon correlation spectroscopy using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). For size determination, a sample of the dispersion was diluted to the appropriate concentration with Milli-Q water and analysis was performed at 25°C with an angle detection of 90°. Zeta potential was measured using a disposable zeta cuvette with the same instrument.
In-vivo study
Ocular pharmacoscintigraphic and intraocular drug availability experiments were carried out using New Zealand Albino rabbits (2.25 ± 0.25 kg). The study was carried out under the guidelines of CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Culture, Government of India). The protocol was approved by the Institutional Animal Ethics Committee, Jamia Hamdard, New Delhi (approval no. 822) and the ARVO guidelines for animal usage were followed. Utmost care was taken to ensure that animals were treated in the most humane and ethically acceptable manner.
Ocular retention study: gamma-scintigraphy
The precorneal retention of nanoparticles after topical administration was assessed by γ-scintigraphy. The radiolabeling of GCV loaded formulations were achieved by using 99m Tc as per the protocol developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, India (14) . Labeling efficiency was determined using instantaneous thin layer chromatography (ITLC) and was found to be > 98%. Corneal retention of chitosan-containing 99m Tclabeled GCV-CSNPs and GCV-NDs were compared with chitosanlacking 99m Tc labeled GCV-NPs. A total of 20 μL of the labeled formulations were instilled into the cul-de-sac of the left eye of the rabbit, and the eye was manually blinked three times to distribute the formulation over the cornea. The right eye of each rabbit served as a negative control. A gamma camera (Millenium VG, Milwaukee, Wisconsin), autotuned to detect the 140 KeV radiation of Tc-99m, was used for the scintigraphy study. Rabbits were anesthetized by using a ketamine HCl injection given intramuscularly at a dose of 15 mg/kg body weight and positioned 5 cm in front of the probe before the radio imaging. Recording was started 5 s after instillation and continued for 30 min using 128 × 128 pixel matrix. Sixty individual frames (60 × 30 s) were captured by dynamic imaging process. The region of interest (ROI) was selected on one frame of the image, and the time activity curve was plotted to calculate the rate of disappearance from the eye surface. ROI activity of all the images were recorded on a computer system assisted with the software Entegra Version-2.
Ocular drug delivery study: aqueous humoral drug concentration profile
Four groups, each with seven New Zealand Albino rabbits (2.25 ± 0.25 kg), were used. The protocol was approved by the Institutional Animal Ethics Committee, Jamia Hamdard, New Delhi, India and corresponding guidelines were followed. Each group received, in both the eyes, a single topical instillation (50 μL) of GCVsolution, GCV-NPs, GCV-CSNPs and GCV-NDs at a GCV dose equivalent to 0.3% w/v of GCV (3 mg/mL). The eyes were anesthetized after the treatment using topical application of 4% xylocaine sterile solution (AstraZeneca LP); 50 μL of the aqueous humor was collected using 30 gauze needles pre-and post-treatment at 0.5, 1, 2, 4, 6, 8 and 12 h. All aqueous humor samples were collected in pre-labeled eppendorf tubes for UPLC analysis, sealed and stored at -20°C until UPLC analysis. The aqueous humor samples were prepared as mentioned above. Pharmacokinetic parameters (PK) were calculated by non-compartmental analysis (model independent analysis using WinNonLin version 4.0 (Pharsight Corp., Mountain View, CA, USA).
Sample preparation
All the rabbit aqueous humor samples were stored at -20°C and allowed to thaw at room temperature prior to sample preparation. A 50 μL aliquot of rabbit aqueous humor was pipetted into a 1.0 mL eppendorf tube, followed by the addition of 100 μL of acetonitrile. The samples were vortexed for 5 min followed by 5 min of centrifugation at 10,000 rpm. The samples were filtered through a 0.22 μm nylon filter and 5 μL of the filtrate was directly injected into the UPLC system
Ocular tolerance test
The potential ocular irritancy of GCV-NPs, GCV-CSNPs and GCV-NDs were evaluated according to a modified Draize test (15) using a slitlamp. The congestion, redness and swelling, and tear discharge of the conjunctiva were graded on a scale from 0 to 3, 0 to 4, and 0 to 3, respectively. Nanoparticles (50 μL) were topically applied in the right eye (every 10 min for 1 h) and the left eyes were used as controls. Observation of the ocular tissue condition was performed at 12 h and 24 h after the end of the experiments.
Results and discussion
Preparation and characterization of GCV nanocarriers
We designed PLGA-and Span-based nanoparticles (niosomes) coated with a chitosan coating to increase the mucoadhesivness and as a result the retention time after instillation onto the eye cornea was improved. The mean of GCV entrapment (%) in GCV-NPs, GCV-CSNPs and GCV-NDs were 49.3%, 46.7% and 47.2%, respectively. The TEM and the particle size distribution of the GCV nanoformulations are shown in Figures 1 and 2 , respectively. The micrographs of the chitosan-coated GCV-CSNPs and GCV-NDs demonstrated a very different appearance as compared to the reference GCV-NPs ( Figure 1B and C) . Spherical-shaped particles with a double layer structure were observed in case of chitosan-coated nanoformulations indicating the existence of chitosan surrounding the GCV-CSNPs and GCV-NDs. The hydrophilic polymer coating of PLGA and surfactant based nanoparticles would depend on the capability of the polymer to adhere to the hydrophobic layer. The interaction between chitosan and such particles surface area due to a combination of physical adsorption, hydrophobic interaction and bridging between them. In general, all of the three formulations, GCV-NPs, GCV-NDs, and GCV-CSNPs were equally round in shape with a mean particle size in the range of 180-200 nm ( Figure 2 ). The polydispersity index (PI), which is a measure of uniformity of size within the formulation (1, 16), was also measured. The GCV-NDs exhibited a more narrow size distribution (PI, 0.181) compared to GCV-CSNPs (PI, 0.65) and GCV-NPs (PI, 1.15), with a mean size of 190 nm, 200 nm and 190 nm, respectively. The zeta potential of GCV-NPs, GCV-NDs, and GCV-CSNPs were -23.4 mV, +41.8 mV and +37.2 mV, respectively. The zeta potential is an important particle characteristic indicating the surface charge that can influence the nano-suspension as well as the mucoadhesion into the ocular surface. The electrostatic charge repulsion between the similar charge (either positive or negative) particles prevents the aggregation and thus ensure the dispersed state of the nanosuspension. On the other hand, positive surface charge (illustrate by positive zeta potential value) on the particles is responsible for mucoadhesion with mucin layer. In the present study, positive value zeta potential of GCV-NDs, and GCV-CSNPs provided the proof of successful chitosan adsorbed cationic surface modification of niosomes and GCV-NPs. Moreover, all the three formulations showed good dispersion stability.
Rabbit studies Ocular retention
Gamma-scintigraphy is a well-established technique for the in-vivo monitoring of the fate of nanocarriers (14) . After administration of the radiolabeled ophthalmic formulation, a good spreading was observed over the entire precorneal area. The quantification of radioactivity in ROIs enabled the assessment of the remaining acti vity at different time points after instillation.
Radioacti vity values counted in the ROI on gamma scintigraphic dynamic whole body images collected for the first 30 min after administration of the reference (chitosan lacking) and chitosan-coated formulations (radioactivity versus time profile) is shown in Figure  3 . As expected, the clearance of the reference (chitosan lacking) PLGA nanoparticles (GCV-NPs) from the ocular surface was most rapid. This can be explained by the lack of mucoadhesion with the cornea. In contrast, the chitosan-containing GCV-CSNPs and GCV-NDs were retained on the ocular surface significantly longer (p < 0.05) than GCV-NPs ( Figure 3A-C) . The AUC 0-30 min for the retained activity of GCV-CSNPs and GCV-NDs were 47,505 and 39,431, respectively, which is about 4-fold higher as compared to the reference GCV-NPs with a value of 11,032. These findings advocate that the presence of chitosan in the formulations serves to prolong the retention of the nanoparticles on the corneal surface. Particularly, due to the interaction of positively charged chitosan with the cornea surface which is negatively charged by the pre sence of mucin and other components (4, 7) . Moreover, the uniform and spherical large surface area increased the spreading and contact time of the mucoadhesive nanoparticles over the corneal surface thereby promoting the corneal retention (17) . 
Intraocular aqueous humoral drug delivery
Aqueous humor GCV concentration-time profiles upon topical instillation of GCV solution, GCV-CSNPs, GCV-NPs and GCV-NDs to the rabbit eye are shown in Figure 4 . Calculated kinetic parameters are shown in Table 1 . In the group treated with the GCV solution, a relatively low ocular bioavailability (AUC 0-t , 495 ± 11 ng·h/mL) was observed; the aqueous humor levels of the drug were undetectable after 2 h, which can be attributed to rapid pre-corneal loss. Administration of the reference, chitosan-lacking GCV-NP formulation yielded an about 3-fold higher value (1361.4 ± 12.0 ng·h/mL) compared to the GCV solution indicating that incorporation in nanosized PLGA particles can improve the permeation by improving corneal retention (12, 17) . Topical instillation of GCV-CSNPs and GCV-NDs even more enhanced the humoral drug concentration with nearly similar availability of 3991 ± 20 and 3428 ± 29 ng·h/mL, respectively. The humoral drug availability was approx. 7-to 8-fold higher as compared to the GCV solution and approx 2.5-fold higher as compared to the reference GCV-NPs.
Our results indicate that both chitosan-coated GCV Mean values ± SD (n = 14; both eyes of each rabbit out of the seven rabbits were used). nanoparticle formulations provided higher aqueous humoral drug availability as compared to a GCV solution and the chitosan-lacking reference nanoparticles. This can be attributed to an increased corneal retention of the GCV nanoformulations, providing a larger time frame for sustained release of the entrapped drug. Furthermore, the large surface area provided by nanosized particles increased the spreading and contact time over the corneal surface which favours the corneal retention. Clearly, the significantly increased corneal retention mediated by the mucoadhesiveness conferred by chitosan contributes strongly to the improvement of the transcorneal drug permeation (7, 17) .
Ocular tolerance study
For such a nanometric delivery system to be proposed as an ophthalmic nanomedicine, it is important not only to examine the biopharmaceutical properties but also their non-irritant nature. Therefore, in-vivo ocular irritation test for GCV-NP, GCV-CSNPs, GCV-NDs were evaluated by using modified Draize test. The in-vivo result of ocular irritation test in rabbits showed no visual sign of irritation or other tissue damaging effect to anterior ocular tissues (data were not given). Moreover, there were no excessive tear formation and the clinical scores for conjunctival swelling, corneal opacity and discharge were always zero in the case of treatment group of all the formulation during the study phase. The results confirmed that the studied formulations were non-irritant and well tolerated.
Conclusion
Entrapment of GCV in PLGA nanoparticles and niosomes increases the GCV concentration in the aqueous humor.
Coating of the surface of the nanoparticles with chitosan further promotes the corneal drug absorption process by virtue of an increased retention on the ocular surface. Therefore, we propose that chitosan-coated nanoparticles are promising carriers for GCV in novel topical ophthalmic nanoformulations.
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